» Articles » PMID: 33000297

Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions

Overview
Journal AAPS J
Specialty Pharmacology
Date 2020 Oct 1
PMID 33000297
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Extending licensed drug use to the pediatric population has become an essential part of the drug development process. Nonetheless, ethical concerns limit clinical testing in pediatric populations and data collected from oral bioavailability and food effect studies in adults are often extrapolated to the target pediatric (sub)populations. However, based on published information, food effects on drug absorption in infants may not be adequately evaluated by data collected in adults. In the present study, a physiologically based pharmacokinetic (PBPK) approach for modeling paracetamol suspension data collected in adults was proposed with the ultimate aim to investigate whether extrapolation to infants is substantially affected by the dosing conditions applied to adults. The development of the PBPK model for adults was performed using GastroPlus™ V9.7, and after scaling to infants considering physiological, anatomical, and drug clearance changes, extrapolation of the different dosing conditions was performed by applying dosing conditions dependent on changes on the paracetamol gastric emptying process. Successful simulations of previously observed plasma concentration levels in infants were achieved when extrapolating from fasted and infant formula-fed conditions data. Data collected following the reference meal appeared less useful for simulating paracetamol suspension performance in infants. The proposed methodology deserves further evaluation using high-quality clinical data both in adults and in infants.

Citing Articles

The Use of Population Pharmacokinetics to Extrapolate Food Effects from Human Adults and Beagle Dogs to the Pediatric Population Illustrated with Paracetamol as a Test Case.

Gasthuys E, Sandra L, Statelova M, Vertzoni M, Vermeulen A Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256887 PMC: 10818831. DOI: 10.3390/ph17010053.


Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.

Pawar G, Wu F, Zhao L, Fang L, Burckart G, Feng K AAPS J. 2023; 25(4):67.

PMID: 37386339 DOI: 10.1208/s12248-023-00826-1.


Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.

Najjar A, Punt A, Wambaugh J, Paini A, Ellison C, Fragki S Arch Toxicol. 2022; 96(12):3407-3419.

PMID: 36063173 PMC: 9584981. DOI: 10.1007/s00204-022-03356-5.


Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.

Guimaraes M, Vertzoni M, Fotaki N AAPS J. 2022; 24(1):27.

PMID: 35013803 PMC: 8816611. DOI: 10.1208/s12248-021-00662-1.